In our study, we found that mitoTEMPO, a mitochondrial antioxidant agent, and MCC950, a specific NLRP3 inhibitor, could downregulate the expression of the NLRP3 inflammasome and alleviate renal fibrosis in the siBNIP3+hypoxia group in HK-2 cells. This evidence concerns the gene NLRP3 and renal fibrosis.